scorecardresearch
Thursday, August 28, 2025
TopicCovaxin

Topic: Covaxin

Good news for kids: Expert panel gives Covaxin emergency approval for 2-18-year-olds

The phase 2/3 clinical trials for Covaxin for children were completed last month. The SEC will now send its recommendations to DCGI.

SII, Bharat Biotech get nod to export 10 lakh Covid vaccine doses under ‘Vaccine Maitri’

Ten lakh doses of Covaxin would be sent to Iran and 10 lakh doses of Covishield will be exported each to Myanmar, Nepal & Bangladesh under the ‘Vaccine Maitri’ programme in October.

The three factors influencing India’s December deadline for Covid vaccination

The goal of vaccinating all adults by 31st December 2021 is not as unrealistic as it may have seemed earlier.

Vaccine makers upset over ‘differential pricing’ for ZyCov-D, and lack of clarity on exports

ZyCov-D has reportedly been priced by the company at Rs 1,900 for three doses while the others cost between Rs 205-215 per dose.

Decision on Bharat Biotech’s Covaxin emergency use listing will be made in October, WHO says

The status of assessment for Covaxin is ongoing. Bharat Biotech said it submitted data pertaining to its Covid vaccine to WHO on 19 April and is awaiting feedback for the same.

How Sri Lanka is facing an economic disaster after overnight switch to total organic farming

A selection of the best news reports, analysis and opinions published by ThePrint this week.

Centre places order with Serum Institute of India for 66 crore Covishield doses

SII has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month, and the latest consignment ordered by Centre is to be supplied by December.

In India’s vaccination race, Covishield at 88% beats Covaxin hands down

Govt data shows that 65.28 crore doses have been administered. Of this, Covaxin accounts for just 12.1% of doses administered.

At 16.4 cr doses, SII’s increased Covishield output helps India cross Aug vaccination target

Modi govt, which projected 15 crore doses would be available in August, managed to achieve its 1 crore-doses-a-day plan last week. Meanwhile, Covaxin production lags.

Bharat Biotech’s Ankleshwar plant, manufacturer of rabies vaccine, rolls out 1st batch of Covaxin

Health Minister Mansukh Mandaviya released the first commercial batch of Covaxin from the Gujarat plant Sunday, said it had the capacity to produce more than 1 crore doses per month.

On Camera

How economic planning stifled India’s growth and talent

The Indian planning system did not encourage individuals based on ‘what they knew’, but on ‘whom they knew’. Many left for countries that recognised their talent.

All bets off as online gaming bill shakes industry & key players suspend ‘gambling’ on their platforms

The new law, which the government has framed as a moral duty, forced major platforms like Dream11 & Zupee to shut operations, wiping out hundreds of crores in market capitalisation. 

Post-Sindoor, joint doctrine tasks Special Forces with fighting info warfare & countering propaganda

Joint Doctrine for Special Forces Operations, released Wednesday, also outlines plans for the future expansion of AFSOD and the creation of Joint Service Training Institutes.

That Oval Office picture for ages deserves closer Indian reading, with a geopolitical lens

Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.